Tumor organoids

Patient-derived models for the next-gen drug discovery and development

Reduce oncology drug attrition rates

Predict patient response before moving your drug to the clinic

HUB Organoids are unique patient-derived in vitro models developed directly from patient biopsies or resections. Our living tumor biobank includes:

  • genetically stable organoid models
  • a wide range of carcinoma indications
  • matched primary tumor and healthy tissue-derived organoids
  • organoids derived from both primary and metastatic lesions

Using HUB´s drug screening platform, clinically-relevant data can be generated that allows you to identify new targets, refine your drug combination strategies, or stratify your patient population with confidence.

Download our fact sheet

patient population

Identify responders and non-responders

Prospectively identify your target patient population and investigate the mechanism of response in patients.


Test combination strategies

Identify the most promising combo startegy with the only easily scalable patient-derived in vitro system. 


Discover predictive biomarkers

Predict therapeutic outcome using models that recapitulate original patient pathophysiology and preserve patient- and cancer-specific mutations.